Sanara MedTech Expands Distributors to 450+, Q1 Revenue Guidance Up 14-16%
Sanara MedTech’s full-year 2025 adjusted EBITDA surged 86% to $17 million and cash from operations jumped to $6.8 million from a $24,000 outflow, while Q4 net loss narrowed to $1.1 million from a $0.9 million gain a year earlier. The company expanded its distributor network to over 450 partners and forecasted Q1 2026 revenue of $26.7–$27.2 million, a 14–16% increase year-over-year.
1. Q4 and Full Year Financial Results
Sanara MedTech reported a Q4 net loss from continuing operations of $1.1 million versus net income of $0.9 million in the prior year, generating EPS of $0.04 against a consensus estimate of $0.11. The company used $5.3 million winding down its Tissue Health Plus segment in H2 2025, below initial projections, and posted full-year adjusted EBITDA of $17 million, up 86%, alongside $6.8 million of cash from operations compared to a $24,000 outflow in 2024.
2. Commercial Expansion
By year-end 2025, Sanara MedTech grew its contracted distributor network to over 450 partners, up from more than 350 the prior year, and increased its presence in healthcare facilities to over 1,450 locations versus 1,300. This expansion supports broader market penetration for the company’s surgical wound care products.
3. 2026 Outlook and Strategic Priorities
Sanara MedTech guided Q1 2026 net revenue of $26.7–$27.2 million, representing 14–16% year-over-year growth, driven in part by a newly effective Vizient group purchasing contract providing access to 1,800 accounts. Strategic priorities include deeper surgical wound market penetration, investment in field sales and R&D, and commercialization of Astec through the BMI partnership to sustain growth and profitability.